[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-aggregator-ars-pharmaceuticals-inc-nasdaq330194d846-2628-7b61-8f9e-2d8418dc2877":3},{"id":4,"timestamp":5,"title":6,"content":7,"link":8,"preview":9,"tags":10,"predictedTags":11,"showTags":12,"source":13,"reactions":14,"selfReactions":15,"logo":16,"sourceId":17,"sourceUserId":18,"asset":19,"tagsCategories":20,"totalComments":21,"lang":22,"unique_views_count":21},"ars-pharmaceuticals-inc-nasdaq330194d846-2628-7b61-8f9e-2d8418dc2877","1738794915000","ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,000 Shares","ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 50,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the completion of the sale, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.","https://www.marketbeat.com/instant-alerts/ars-pharmaceuticals-inc-nasdaqspry-director-laura-shawver-sells-50000-shares-2025-02-04/","https://www.marketbeat.com/images/marketbeat-logo-1200-1200.jpg?v=1","[]","[\"-\",\"ARS\"]","[{\"name\":\"-\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/protocols/-.png\"},{\"name\":\"ARS\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/protocols/ars.png\"}]","33",[],[],"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/news-feeds/sources/market-beat.png","Market Beat",null,"","[\"Other\"]","0","EN"]